Prospective Multicenter Observational Study of Anlotinib in Advanced Non-Small Cell Lung Cancer: Real-World Evidence From China.

Aged ≥ 70 years ( p = 0.022) remained significantly associated with worse OS, while ≥ 3 metastatic sites ( p = 0.065) showed a trend towards an association with poorer OS. 3.3 Efficacy of Different Treatment Regimens of Anlotinib Regarding the different combination regimens, median PFS and OS varied numerically across subgroups receiving anlotinib monotherapy (PFS, 5.6 months; OS, 11.3 months), anlotinib plus chemotherapy (PFS,

also in 53,322 other papers